Clinical Trial Update: A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial compares belzutifan in combination with palbociclib versus belzutifan alone in participants with advanced renal cell carcinoma; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• Welireg (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING